

## PRESCRIBER INSTRUCTIONS:

- 1. Have your patient read page 3 (section 10): PATIENT AUTHORIZATION(S). Request that the patient sign the top section** to allow Acthar Patient Support to provide a complete level of support during the approval process. **If the patient would like to receive support, please have them sign the second section** to enroll in support and educational programs to receive additional information about their condition and treatment.
- 2. Complete pages 1 and 2 of the Acthar Referral Form.** Check the Acthar Injection Training Services box at the bottom of page 1 to request no-cost injection training for your patient.
- 3. Fax the completed Acthar Referral Form along with copies of the patient's pharmacy benefits card(s) (both front and back) to 1-877-937-2284.**
- Acthar Patient Support will process the Acthar Referral Form and contact both you and your patient.
- Prior authorization assistance will only be provided for indicated disease states. Medicare, Medicaid, and other federal or state program healthcare patients may be ineligible for certain other aspects of Acthar assistance programs.

## PRESCRIBER SIGNATURE ON PAGE 1 AUTHORIZES PRESCRIPTION, CONSENT, AND STATEMENT OF MEDICAL NECESSITY

**By signing page 1**, I certify that Acthar<sup>®</sup> Gel is medically necessary for this patient and that I have reviewed this therapy with the patient and will be monitoring the patient's treatment. I verify that the patient and Prescriber information on this enrollment form was completed by me or at my direction and that the information contained herein is complete and accurate to the best of my knowledge. I understand that I must comply with my practicing state's specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to me by the dispensing pharmacy.

I authorize United BioSource LLC ("UBC"), the current operator of Acthar Patient Support, and other designated operators of the Program to perform a preliminary and on-going assessment of benefit verification for this patient and furnish information requested by the patient's insurer that is available on this form. I understand that insurance verification is ultimately the responsibility of the Prescriber and third-party reimbursement is affected by a variety of factors. While UBC tries to provide accurate information, they and Mallinckrodt make no representations or warranties as to the accuracy of the information provided.

I understand that representatives from the Program or UBC may contact me or my patient for additional information relating to this prescription. I acknowledge and agree that this prescription may be sent to and received by the designated Specialty Pharmacy by any means under applicable law, including via a designated third party or other operator of the Program, and that no additional confirmation of receipt of prescription is required by the designated Specialty Pharmacy.

Prescriber authorizes UBC to use the Surescripts network on Prescriber's behalf in connection with this enrollment form. Prescriber will comply with all Surescripts terms and conditions including confidentiality, commercial messaging, privacy and security, applicable laws, and use of data. All Surescripts disclaimers apply. A full list of terms and conditions is available at [www.ubc.com/surescriptsterms](http://www.ubc.com/surescriptsterms).

## PATIENT INSTRUCTIONS:

Your Prescriber will submit the completed Acthar Referral Form to Acthar Patient Support. After we receive the form, we will call you so we can help you get your medicine. Please be on the lookout and answer calls from 1-800, 1-888, or blocked numbers. If you have any questions, please call **1-888-435-2284** Monday through Friday from 8 AM to 9 PM ET or Saturday from 9 AM to 2 PM ET.



# Acthar<sup>®</sup> GEL

(repository corticotropin injection) 80 U/mL

SENT PRESCRIPTION DIRECTLY TO SPECIALTY PHARMACY.  
PLEASE ENROLL PATIENT IN ACTHAR PATIENT SUPPORT.

PHARMACY NAME: \_\_\_\_\_

FAX: 1-877-937-2284

## Acthar Referral Form

Please complete Referral Form and fax toll-free

TEL: 1-888-435-2284

Monday through Friday (8:00 AM to 9:00 PM ET)

Saturday (9:00 AM to 2:00 PM ET)

### 1. PATIENT INFORMATION Patient has been notified of referral YES NO

PATIENT FIRST NAME		PATIENT MIDDLE INITIAL		PATIENT LAST NAME		DATE OF BIRTH	GENDER
HOME ADDRESS				CITY		STATE	ZIP
SHIPPING ADDRESS (IF NOT HOME ADDRESS)		CARE OF (IF NOT ADDRESSED TO PATIENT)		CITY		STATE	ZIP
HOME PHONE	MOBILE	<input type="checkbox"/> OK TO TEXT			BEST TIME TO CALL		
EMAIL ADDRESS				PREFERRED LANGUAGE IF NOT ENGLISH			
ALTERNATIVE CONTACT NAME		TELEPHONE	<input type="checkbox"/> VOICEMAIL APPROVAL		EMAIL	RELATIONSHIP TO PATIENT	

### 2. INSURANCE INFORMATION (Please include copies of front and back of all medical and prescription insurance cards)

PHARMACY BENEFITS	SUBSCRIBER ID #	GROUP #	TEL #
PRIMARY MEDICAL INSURANCE	SUBSCRIBER ID #	GROUP #	TEL #

### 3. PRESCRIBER INFORMATION

PREScriBER FIRST NAME	PREScriBER MIDDLE INITIAL	PREScriBER LAST NAME	NPI #	GROUP NPI # (IF APPLICABLE)	STATE LICENSE #
SPECIALTY: <input type="checkbox"/> PULMONOLOGY <input type="checkbox"/> RHEUMATOLOGY <input type="checkbox"/> OTHER (PLEASE INDICATE) _____					
FACILITY NAME		TELEPHONE	FAX		
ADDRESS		CITY	STATE	ZIP	
OFFICE CONTACT NAME		CONTACT TELEPHONE	MOBILE NUMBER	CONTACT EMAIL ADDRESS	
PREFERRED METHOD OF COMMUNICATION: <input type="checkbox"/> OFFICE PHONE <input type="checkbox"/> MOBILE PHONE <input type="checkbox"/> FAX <input type="checkbox"/> EMAIL <input type="checkbox"/> TEXT <input type="checkbox"/> NO PREFERENCE PREFERRED CONTACT TIME: _____					

### 4. PRESCRIPTION: ACTHAR<sup>®</sup> GEL NDC# 63004-8710-1 5 mL multidose vial containing 80 USP units per mL

#### 4A. PLEASE SELECT AN FDA-APPROVED RECOMMENDED DOSE OR OTHER DOSE

40 UNITS, 2 TIMES A WEEK  80 UNITS, 2 TIMES A WEEK

OTHER DOSE: \_\_\_\_\_ UNITS  mL

SCHEDULE/FREQUENCY: \_\_\_\_\_

ROUTE OF ADMINISTRATION:  INTRAMUSCULAR  SUBCUTANEOUS

QUANTITY OF 5 mL MULTIDOSE VIALS: \_\_\_\_\_ REFILLS: \_\_\_\_\_

#### 4B. TAPER INSTRUCTIONS See attached taper schedule for Additional Taper Instructions

ADDITIONAL SPECIAL INSTRUCTIONS, TITRATION OR TAPER DOSE, IF APPLICABLE:

#### 4C. ALLERGIES

PLEASE PROVIDE ALLERGY INFORMATION, IF APPLICABLE (Additional space provided on page 2):

4D. ICD-10 CODE: \_\_\_\_\_

PRIMARY DIAGNOSIS CODES CAN BE FOUND ON PAGE 2, SECTION 6.

#### 4E. IDENTIFYING SUPPLIES IS MANDATORY FOR A COMPLETE PRESCRIPTION

SYRINGE SIZE: QUANTITY

1 mL  3 mL  Other: \_\_\_\_\_ TOTAL: \_\_\_\_\_

NEEDLE SIZE FOR DRAWING: QUANTITY

20 G needle, 1"  NONE TOTAL: \_\_\_\_\_

NEEDLE SIZE FOR INJECTION: QUANTITY

25 G needle, 5/8"  23 G needle, 3/4"

23 G needle, 1"  25 G needle, 1"

Other: \_\_\_\_\_

Pharmacy to dispense sufficient supplies to complete course of therapy  Sharps Container

(Checking this box will supercede any quantities listed above for individual needles)

### 5. COMMERCIAL STARTER PROGRAM Program for commercial or privately insured patients and new to Acthar. See T&Cs on page 3 for eligibility.

ICD-10 CODE: \_\_\_\_\_ PRIMARY DIAGNOSIS CODES CAN BE FOUND ON PAGE 2, SECTION 6.

Starter product is optional and available at no cost to eligible patients for prompt access to therapy while working through the reimbursement process. Eligible patients must have a valid prescription for the FDA-approved indication of symptomatic sarcoidosis, have not used Acthar Gel (currently or in the past 36 months), have verified commercial or private insurance, and are not participating in Medicare, Medicaid, or any government-funded healthcare plan. See page 3 for terms and conditions.\* This prescription will be forwarded to RxCrossroads by McKesson for pharmacy scheduling and dispensing with the patient for each vial shipment.

DOSE: \_\_\_\_\_ UNITS  mL

SCHEDULE/FREQUENCY: \_\_\_\_\_

ROUTE OF ADMINISTRATION:  INTRAMUSCULAR  SUBCUTANEOUS

QUANTITY OF 5 mL MULTIDOSE VIALS: \_\_\_\_\_ 1 REFILLS: \_\_\_\_\_

ADDITIONAL SPECIAL INSTRUCTIONS, TITRATION OR TAPER DOSE, IF APPLICABLE

#### IDENTIFYING SUPPLIES IS MANDATORY FOR A COMPLETE PRESCRIPTION

SYRINGE SIZE: QUANTITY

1 mL  3 mL  Other: \_\_\_\_\_ TOTAL: \_\_\_\_\_

NEEDLE SIZE FOR DRAWING: QUANTITY

20 G needle, 1"  NONE TOTAL: \_\_\_\_\_

NEEDLE SIZE FOR INJECTION: QUANTITY

25 G needle, 5/8"  23 G needle, 3/4"

23 G needle, 1"  25 G needle, 1"

Other: \_\_\_\_\_

Pharmacy to dispense sufficient supplies to complete course of therapy  Sharps Container

(Checking this box will supercede any quantities listed above for individual needles)

### ACTHAR INJECTION TRAINING SERVICES

By checking here, I request that company-funded Acthar Injection Training Services be arranged for my patient. I understand that Acthar Injection Training Services are available for multiple visits but are NOT a home health nursing service. Patients can contact their Nurse Navigator at any time about injection training.

**PREScriBER SIGNATURE: Please sign only ONE LINE below** (by signing below you are agreeing to the Prescriber Consent section on the cover page of this document)

DISPENSE AS WRITTEN \_\_\_\_\_ DATE  SUBSTITUTIONS ALLOWED \_\_\_\_\_ DATE

Prescriber signature required for consent and to validate prescriptions. Prescriber attests that this is her/his signature. NO STAMPS.

By signing, Prescriber certifies that the above is medically necessary.

**6. DIAGNOSIS AND MEDICAL INFORMATION**

**DIAGNOSIS CODES**

Please check all diagnosis codes that correspond with patient's diagnosis. Below is a list of common ICD-10 codes. You may also write in the patient's diagnosis in the "OTHER" section.

- |   |  |  |  |
|---|--|--|--|
| <input type="checkbox"/> SARCOIDOSIS OF LUNG<br><b>D86.0</b>                                    | <input type="checkbox"/> MULTIPLE CRANIAL NERVE PALSIES<br>IN SARCOIDOSIS<br><b>D86.82</b> | <input type="checkbox"/> SARCOID MYOSITIS<br><b>D86.87</b>           | <input type="checkbox"/> OTHER:<br>_____ |
| <input type="checkbox"/> SARCOIDOSIS OF LYMPH NODES<br><b>D86.1</b>                             | <input type="checkbox"/> SARCOID IRIDOCYCLITIS<br><b>D86.83</b>                            | <input type="checkbox"/> SARCOIDOSIS OF OTHER SITES<br><b>D86.89</b> | _____                                    |
| <input type="checkbox"/> SARCOIDOSIS OF LUNG WITH<br>SARCOIDOSIS OF LYMPH NODES<br><b>D86.2</b> | <input type="checkbox"/> SARCOID PYELONEPHRITIS<br><b>D86.84</b>                           | <input type="checkbox"/> SARCOIDOSIS, UNSPECIFIED<br><b>D86.9</b>    | _____                                    |
| <input type="checkbox"/> SARCOIDOSIS OF SKIN<br><b>D86.3</b>                                    | <input type="checkbox"/> SARCOID MYOCARDITIS<br><b>D86.85</b>                              |  | _____                                    |
| <input type="checkbox"/> SARCOID MENINGITIS<br><b>D86.81</b>                                    | <input type="checkbox"/> SARCOID ARTHROPATHY<br><b>D86.86</b>                              |  | _____                                    |

**ORGAN INVOLVEMENT**

- |                                      |   |   |                                 |  |  |
|--------------------------------------|---|---|---------------------------------|--|--|
| <input type="checkbox"/> Lungs       | <input type="checkbox"/> Skin and tissues | <input type="checkbox"/> Brain and nervous system                                 | <input type="checkbox"/> Spleen | <input type="checkbox"/> Salivary glands | <input type="checkbox"/> Other:<br>_____ |
| <input type="checkbox"/> Lymph nodes | <input type="checkbox"/> Eyes             | <input type="checkbox"/> Bones, joints, cartilage, ligaments, tendons and muscles | <input type="checkbox"/> Liver  | <input type="checkbox"/> Sinuses         | _____                                    |
|                                      | <input type="checkbox"/> Heart            | <input type="checkbox"/> Kidneys and urinary tract                                |                                 |  | _____                                    |

**7. HISTORY OF CORTICOSTEROID USE (IF APPLICABLE) PLEASE ADD DETAILS IN SECTION 9 BELOW.**

PLEASE CHECK ALL THAT APPLY:

A corticosteroid **was** tried with the following response(s):

- Corticosteroid use failed, but same response not expected with Acthar
- Patient hypersensitive or allergic to corticosteroids
- Patient intolerant of corticosteroids
- Other: \_\_\_\_\_

OR

A corticosteroid **was not** tried due to the following response(s):

- Corticosteroid use is contraindicated for this patient
- Intravenous access is not possible for this patient
- Patient has known intolerance to corticosteroids
- Other: \_\_\_\_\_

**8. CONCURRENT MEDICATIONS**

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**9. RELEVANT TREATMENT HISTORY (INCLUDING RECENT CORTICOSTEROID HISTORY. ATTACH ADDITIONAL CASE NOTES AS NECESSARY.)**

Therapy Name	Dose	Start Date	Stop Date (if applicable)	Explain Outcome With Detail (eg, type of outcome)

**OTHER RELEVANT CLINICAL INFORMATION (INCLUDING ALLERGIES)**

NKDA - No known drug allergies

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**PRESCRIBER SIGNATURE: REQUIRED FOR DOCUMENTATION**

I verify that the patient and Prescriber information on this enrollment form was completed by me or at my direction and that the information contained herein is complete and accurate to the best of my knowledge. I certify that my patient has agreed in writing to be contacted by Program administrators or UBC and be furnished with Program or other information or materials.

**10. PATIENT AUTHORIZATION(S)**

**Patient Consent to allow Acthar Patient Support Team to work together with your insurance provider, pharmacy, advocacy organization and others to provide support on your behalf.**

By signing this authorization, I authorize my physician(s), my health insurance company and my pharmacy providers (collectively, "Designated Parties") to disclose to Mallinckrodt ARD LLC ("Mallinckrodt"), the distributor of Acthar, and its agents, authorized designees and contractors, including Mallinckrodt reimbursement support personnel and United BioSource LLC ("UBC") or any other operator of Acthar Patient Support on behalf of Mallinckrodt (collectively, "Manufacturer Parties"), health information relating to my medical condition, treatment and insurance coverage (my "Health Information") in order for them to (1) provide certain services to me, including reimbursement and coverage support, patient assistance and access programs, medication shipment tracking, and home injection training, (2) provide me with support services and information associated with my Acthar therapy, (3) serve internal business purposes, such as marketing research, internal financial reporting and operational purposes, and (4) carry out the Manufacturer Parties' respective legal responsibilities. I further agree and acknowledge that one or more representatives of a Manufacturing Party may participate remotely via video conferencing or similar technology in home injection training and related support services for quality control purposes.

Once my Health Information has been disclosed to Manufacturer Parties, I understand that it may be redisclosed by them and no longer protected by federal and state privacy laws. However, Manufacturer Parties agree to protect my Health Information by using and disclosing it only for the purposes detailed in this authorization or as permitted or required by law.

I understand that I may refuse to sign this authorization and that my physician and pharmacy will not condition my treatment on my agreement to sign this authorization form, and my health plan or health insurance company will not condition payment for my treatment, insurance enrollment or eligibility for insurance benefits on my agreement to sign this authorization form. I understand that my pharmacies and other Designated Parties may receive payment in connection with the disclosure of my Health Information as provided in this authorization. I understand that I am entitled to receive a copy of this authorization after I sign it.

I may revoke (withdraw) this authorization at any time by mailing a letter to Acthar Patient Support, 680 Century Point, Lake Mary, FL 32746. Revoking this authorization will end further disclosure of my Health Information to Manufacturer Parties by my pharmacy, physicians, and health insurance company when they receive a copy of the revocation, but it will not apply to information they have already disclosed to Manufacturer Parties based on this authorization. I also know I may cancel my enrollment in a patient support program at any time in writing by contacting Mallinckrodt via fax at 1-877-937-2284 or by calling Acthar Patient Support at 1-888-435-2284. This authorization is in effect for 5 years unless a shorter period is provided for by state law or until the conclusion of any ongoing coverage support, whichever is longer, once I have signed it unless I cancel it before then.


**THIS SECTION MUST BE COMPLETED IN ITS ENTIRETY, INCLUDING DATE**

 \_\_\_\_\_ **X** \_\_\_\_\_  
PATIENT NAME OR LEGAL REPRESENTATIVE      PATIENT SIGNATURE      IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT      DATE

**Patient Consent to receive additional information from Mallinckrodt such as education on your disease and Acthar.**

I authorize Mallinckrodt and its partners to use, disclose, and/or transfer the personal information I supply (1) to contact me and provide me with informational and marketing materials and clinical trial opportunities related to my condition or treatment by any means of communication, including but not limited to text, email, mail, or telephone; (2) to help Mallinckrodt improve, develop, and evaluate products, services, materials, and programs related to my condition or treatment; (3) to enroll me in and provide me with Acthar-related programs and services that I may select or refuse at any time; (4) to disclose my enrollment and use of these services to my prescriber and insurers; and (5) to use my information that cannot identify me for scientific and market research. This authorization will remain in effect until I cancel it, which I may do at any time in writing by contacting Mallinckrodt via fax at 1-877-937-2284 or by calling Acthar Patient Support at 1-888-435-2284. I may request a copy of this signed authorization.

**THIS SECTION MUST BE COMPLETED IN ITS ENTIRETY, INCLUDING DATE**

 \_\_\_\_\_ **X** \_\_\_\_\_  
PATIENT NAME OR LEGAL REPRESENTATIVE      PATIENT SIGNATURE      IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT      DATE

If patient is not present to sign the form, send them to  
**ActharConsent.com**  
and have them sign electronically.

**\*ACTHAR GEL COMMERCIAL STARTER PROGRAM TERMS & CONDITIONS:** Eligible patients for this Program must meet the following criteria: have a valid prescription for the FDA-approved indication of symptomatic sarcoidosis, have not used Acthar Gel (currently or in the past 36 months), have verified commercial or private insurance, and are not participating in Medicare, Medicaid, or any government-funded healthcare plan. This Program is valid for one vial of Acthar Gel at a time as needed; however, the patient will no longer receive Acthar Gel under this Program when the patient receives insurance approval or a final denial of coverage. The patient agrees not to seek reimbursement from any third-party payer for all or any part of Acthar Gel dispensed pursuant to this Program. This Program is void where prohibited by law. Mallinckrodt reserves the right to rescind, revoke, or amend this Program at any time without notice. By participating in this Program, the patient agrees to these terms and conditions.

## IMPORTANT SAFETY INFORMATION

### Contraindications

Acthar is contraindicated:

- For intravenous administration
- In infants under 2 years of age who have suspected congenital infections
- With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar
- In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

### Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment
- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
- Acthar can cause gastrointestinal (GI) bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain GI disorders. Monitor for signs of perforation and bleeding
- Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated
- Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
- Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms
- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Acthar activity
- There may be an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
- Decrease in bone density may occur. Bone density should be monitored in patients on long-term therapy

### Adverse Reactions

- Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased
- The most common adverse reactions for the treatment of infantile spasms (IS) are increased risk of infections, convulsions, hypertension, irritability, and pyrexia. Some patients with IS progress to other forms of seizures; IS sometimes masks these seizures, which may become visible once the clinical spasms from IS resolve

### Pregnancy

- Acthar may cause fetal harm when administered to a pregnant woman

Please see accompanying full Prescribing Information for additional Important Safety Information or visit <https://www.actharhcp.com/Static/pdf/Acthar-PI.pdf>.

## INDICATION AND USAGE

Acthar Gel is indicated for symptomatic sarcoidosis.